Abstract
Several candidate modifier genes which, in addition to the pathogenic CAG repeat expansion, influence the age at onset (AO) in Huntington disease (HD) have already been described. The aim of this study was to replicate association of variations in the N-methyl D-aspartate receptor subtype genes GRIN2A and GRIN2B in the “REGISTRY” cohort from the European Huntington Disease Network (EHDN). The analyses did replicate the association reported between the GRIN2A rs2650427 variation and AO in the entire cohort. Yet, when subjects were stratified by AO subtypes, we found nominally significant evidence for an association of the GRIN2A rs1969060 variation and the GRIN2B rs1806201 variation. These findings further implicate the N-methyl D-aspartate receptor subtype genes as loci containing variation associated with AO in HD.
Introduction
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder characterised by motor disturbances, cognitive decline, and neuropsychiatric symptoms. It is caused by a CAG repeat expansion (>36 repeats) in exon 1 of the HTT gene.[1] The lengths of the expanded CAG tract is inversely related to the age at clinical onset of HD, accounting for more than half of the overall variance in age at onset (AO).[2] Despite this strong correlation, there remains considerable variation of over 40 years in AO in individuals with identical repeat lengths. Several candidate modifier genes of HD have already been described in independent studies.[3],[4],[5],[6],[7],[8],[9] In order to confirm the associations between modifier gene variations and AO, independent replication studies are compulsory. Here, we tested the primary hypothesis of an original study [4], that variations in the NR2A and NR2B glutamate receptor subunit genes (GRIN2A, GRIN2B) explain additional variance in AO for HD.
Methods
The study cohort comprised 1,211 individuals of European ancestry with HD collected by the EHDN “REGISTRY” study prior to October 14, 2008. “REGISTRY” is a multi-centre, multi-national observational study which aims to obtain natural history data on a wide spectrum of the European HD population (http://www.euro-hd.net/html/registry).[10] In order to test previously reported HD genetic modifiers in this cohort, HD patients with available data on age, sex, age at symptom onset, mutant CAG repeat size and body mass index (BMI) were included (initial n = 1211; n = 1069; 529 men and 540 women had a complete data set).
The expanded trinucleotide repeats ranged from 40 to 89 with a mean (± SD) of 45±4.7 CAGs, and AO ranged from 6 to 74 years, with an onset (mean ± SD) of 42 ±11.8 years. AO was defined as the age at which, according to the rater, the first signs of HD appeared. Five hundred and thirty-eight patients first presented with motor disturbances (mean ± SD motor AO = 43.4±11.6 years), 241 with psychiatric problems (mean ± SD psychiatric AO = 39.9±10.8 years), and 112 with cognitive decline (mean ± SD cognitive AO = 38.6±13.1 years). For the remaining patients no specific symptoms were listed (mean ± SD AO = 42.1±11.8 years). Genotyping of three SNPs was conducted as described before.[4]
Results
None of the SNPs deviated from Hardy-Weinberg Equilibrium (HWE). Considering the earliest AO (n = 1,069), we did find evidence of association of the GRIN2A SNP rs2650427 (table). The R2 statistic rose modestly (from 0.634 to 0.635) but significantly (p=0.028) when GRIN2A genotypes were added to the regression model. The analysis did not, however, replicate the association reported between the SNP rs1969060 in intron 2 of the GRIN2A gene and SNP C2664T (rs1806201) in exon 12 of the GRIN2B gene (table); but when dividing the cohort according to the nature of the symptoms presented initially, both the GRIN2B C2664T and the GRIN2A rs1969060 polymorphisms explained a small but considerable amount of additional variance in residual AO in the respective samples. Inclusion of the GRIN2B genotypes in the model for motor AO (n = 538) increased the R2 statistic from 0.620 to 0.623 (p=0.046) and in the study of 241 patients with psychiatric AO, the R2 statistic of the exponential regression rose from 0.515 to 0.523 with the GRIN2A rs1969060 genotypes included (p=0.026, table). Interestingly, the association of cognitive AO (n = 112) with the GRIN2A rs2650427 polymorphism shows the highest nominal significance as compared to the other models in the study (0.770 to 0.775, p=0.014). Yet, the results remain statisticallysignificant when excluding the patients with CAGs over >70 (n=4).
| Model | Genotypes |
CAG mean ± SD |
erliest AO
mean ± SD |
R²* | P value |
| HD CAG 40-89 (n=1069) | 44.97±4.7 | 41.87±11.8 | 0.634 | <0.0005 | |
| + GRIN2B C2664T (rs1806201) | CC (n=560) | 44.94±4.8 | 42.13±12.1 | 0.634 | 0.541 |
| CT (n=436) | 45.02±4.5 | 41.32±11.3 | 0.634 | 0.199 | |
| TT (n=73) | 44.86±4.6 | 43.14±11.9 | 0.634 | 0.196 | |
| additive | 0.634 | 0.973 | |||
| + GRIN2A rs1969060 | TT (n=745) | 44.83±4.5 | 42.00±11.9 | 0.634 | 0.160 |
| TC (n=292) | 45.24±5.1 | 41.67±11.5 | 0.634 | 0.203 | |
| CC (n=32) | 45.75±4.2 | 40.66±11.5 | 0.634 | 0.645 | |
| additive | 0.634 | 0.172 | |||
| + GRIN2A rs2650427 | CC (n=374) | 44.99±4.0 | 41.40±11.9 | 0.634 | 0.125 |
| CT (n=512) | 44.94±5.2 | 41.99±11.9 | 0.634 | 0.891 | |
| TT (n=183) | 42.51±4.2 | 43.14±10.9 | 0.635 | 0.031 | |
| additive | 0.635 | 0.028 | |||
| Model | Genotypes |
CAG mean ± SD |
motor AO
mean ± SD |
R²* | P value |
| HD CAG 40-77 (n=538) | 44.72±4.0 | 43.39±11.6 | 0.620 | <0.0005 | |
| + GRIN2B C2664T (rs1806201) | CC (n=274) | 44.52±3.8 | 44.41±11.8 | 0.622 | 0.099 |
| CT (n=221) | 44.96±4.1 | 41.98±11.1 | 0.623 | 0.046 | |
| TT (n=43) | 44.77±4.9 | 44.07±12.4 | 0.620 | 0.560 | |
| additive | 0.621 | 0.296 | |||
| + GRIN2A rs1969060 | TT (n=373) | 44.51±3.6 | 43.79±11.5 | 0.620 | 0.824 |
| TC (n=153) | 45.32±4.9 | 42.19±11.9 | 0.620 | 0.934 | |
| CC (n=12) | 43.75±2.5 | 46.25±9.5 | 0.620 | 0.658 | |
| additive | 0.620 | 0.744 | |||
| + GRIN2A rs2650427 | CC (n=181) | 44.15±3.8 | 41.99±11.8 | 0.620 | 0.362 |
| CT (n=259) | 44.48±4.1 | 44.00±11.9 | 0.620 | 0.792 | |
| TT (n=98) | 44.60±4.2 | 44.34±10.4 | 0.621 | 0.143 | |
| additive | 0.621 | 0.158 | |||
| Model | Genotypes |
CAG mean ± SD |
psychiatric AO
mean ± SD |
R²* | P value |
| HD CAG 40-67 (n=241) | 44.73±4.1 | 39.86±10.8 | 0.515 | <0.0005 | |
| + GRIN2B C2664T (rs1806201) | CC (n=139) | 44.81±4.4 | 39.50±11.3 | 0.513 | 0.964 |
| CT (n=90) | 44.74±3.8 | 39.79±10.5 | 0.514 | 0.607 | |
| TT (n=12) | 43.67±2.1 | 44.58±9.6 | 0.517 | 0.211 | |
| additive | 0.514 | 0.618 | |||
| + GRIN2A rs1969060 | TT (n=172) | 44.79±4.1 | 39.01±10.9 | 0.523 | 0.026 |
| TC (n=63) | 44.01±3.7 | 42.78±9.8 | 0.523 | 0.033 | |
| CC (n=6) | 49.50±6.8 | 33.50±15.5 | 0.514 | 0.649 | |
| additive | 0.522 | 0.037 | |||
| + GRIN2A rs2650427 | CC (n=83) | 44.79±4.0 | 39.42±11.3 | 0.514 | 0.504 |
| CT (n=120) | 44.24±3.8 | 40.90±10.5 | 0.514 | 0.702 | |
| TT (n=38) | 43.13±5.1 | 37.53±10.8 | 0.514 | 0.724 | |
| additive | 0.514 | 0.514 | |||
| Model | Genotypes |
CAG mean ± SD |
cognitive AO
mean ± SD |
R²* | P value |
| HD CAG 40-89 (n=112) | 46.34±7.8 | 38.60±13.1 | 0.765 | <0.0005 | |
| + GRIN2B C2664T (rs1806201) | CC (n=54) | 46.76±8.5 | 37.89±14.2 | 0.763 | 0.621 |
| CT (n=55) | 45.74±7.1 | 39.73±11.9 | 0.763 | 0.530 | |
| TT (n=3) | 50.00±6.2 | 30.67±14.0 | 0.763 | 0.682 | |
| additive | 0.763 | 0.742 | |||
| + GRIN2A rs1969060 | TT (n=74) | 46.24±7.8 | 38.95±14.1 | 0.763 | 0.682 |
| TC (n=31) | 46.74±8.5 | 37.68±11.4 | 0.763 | 0.799 | |
| CC (n=7) | 45.71±3.8 | 39.00±10.4 | 0.763 | 0.741 | |
| additive | 0.763 | 0.650 | |||
| + GRIN2A rs2650427 | CC (n=40) | 45.55±4.9 | 37.80±12.4 | 0.770 | 0.054 |
| CT (n=55) | 47.67±10.0 | 36.87±13.2 | 0.763 | 0.742 | |
| TT (n=17) | 43.9±3.2 | 46.06±12.3 | 0.772 | 0.033 | |
| additive | 0.775 | 0.014 |
Table Thevariability in AO attributable to the CAG repeat length was assessed by linear regression using the logarithmically transformed AO as the dependent variable and GRIN genotypes as independent variables. *R2 illustrates the relative improvement of the regression model, when the genotypes are considered in addition to the CAG repeats.
In order to control the effect of sex-specific associations, we further analysed each combination of genotype with sex, but there was no trend towards significance. Moreover, on average, psychiatric and cognitive symptoms significantly predate clinical motor onset by 3.5 and 4.8 years (p< 0.001), thus confirming that affective and cognitive symptoms could be early manifestations of neuronal dysfunction.
Discussion
Of the three polymorphisms tested, GRIN2A rs2650427 showed the most consistent evidence of replication in the EHDN Registry study sample. This is in accordance with another replication study in the large set of kindreds from Venezuela, where GRIN2A variation also explained a small but considerable amount of additional variance in residual AO.[5]
Yet, the interpretation of the association of cognitve AO with the GRIN2A rs2650427 polymorphism should be considered with caution since the sample size of this subgroub (n=112) is too small to provide the statistical power required.
Unfortunately, none of the SNPs associated has been validated functionally and it is most likely that the polymorphisms analysed are not the functional variations, but represent markers in linkage disequilibrium with variations that modify the AO. Although, synonymous SNPs like GRIN2B rs1806201 might be pathogenetically relevant via influencing mRNA splicing, protein stability and structure.
The failure to replicate the sex-specific effect of rs1806201 suggests that the original observation may have been false positive, emphasizing the need for stringent statistical thresholds. On the other hand, since linkage disequilibrium is not uniform across populations, the mixed ancestry in the EHDN REGISTRY study sample could account for heterogeneous results. Inconsistent results may also occur because of difficulties in exact AO definitions. The data stresses the need for precise phenotyping in order to reduce heterogeneity, and to facilitate the discovery of clinically relevant biological pathways.
Although the associations replicated explain only a small fraction of the variance of AO, the observed correlations with HD phenotypes demonstrate that GRIN2A and GRIN2B remain promising candidate genes, worth to be studied further in more detail.
Acknowledgments
The authors thank all EHDN Registry Study Group investigators for collecting the data and all participating patients for their time and efforts.
Correspondence to Dr Larissa Arning, Ruhr-University, Department of Human Genetics, Universitätsstr. 150, MA5/39, 44801 Bochum, Germany, larissa.arning@rub.de
Competing interests
The authors have declared that no competing interests exist.
Funding information
The European Huntington’s Disease Network is funded by CHDI Foundation, Inc. CS was supported by FoRUM grant K040-09.
Ethics approval
This study was conducted with the approval of the local ethics committee of the different clinical centres.
Contributor Information
Investigators of the European Huntington's Disease Network:
K Barth, M Bascuñana Garde, R Bos, D Ecker, OJ Handley, N Heinonen, C Held, M Laurà, A Martínez Descals, T Mestre, D Monza, J Naji, M Orth, H Padieu, S Pro Koivisto, A Rialland, P Sasinková, P Trigo Cubillo, M van Walsem, M-N Witjes-Ané, D Zielonka, Raphael M. Bonelli, Brigitte Herranhof, Anna Hödl, Hans-Peter Kapfhammer, Michael Koppitz, Markus Magnet, Daniela Otti, Annamaria Painold, Karin Reisinge, Florian Brugger, Caroline Hepperger, Anna Hotter, Philipp Mahlknecht, Michael Nocker, Klaus Seppi, Gregor Wenning, Pascale Ribaï, Christine Verellen-Dumoulin, Jiří Klempíř, Martin Kucharik, Jan Roth, Lis Hasholt, Lena E. Hjermind, Oda Jakobsen, Jørgen E Nielsen, Anne Nørremølle, Sven Asger Sørensen, Jette Stokholm, Heli Hiivola, Kirsti Martikainen, Katri Tuuha, Christoph Michael Kosinski, Daniela Probst, Christian Sass, Johannes Schiefer, Christiane Schlangen, Cornelius J. Werner, Herwig Lange, Matthias Löhle, Alexander Storch, Anett Wolz, Martin Wolz, Johann Lambeck, Birgit Zucker, Alexander Münchau, Lars Stubbe, Simone Zittel, Walburgis Heinicke, Bernhard Longinus, Alexander Peinemann, Michael Städtler, Adolf Weindl, Stefan Bohlen, Herwig Lange, Ralf Reilmann, Antonie Beister, Matthias Dose, Kathrin Hammer, Gabriele Leythaeuser, Ralf Marquard, Tina Raab, Caroline Schrenk, Michele Schuierer, Alexandra Wiedemann, Antonie Beister, Matthias Dose, Kathrin Hammer, Gabriele Leythaeuser, Ralf Marquard, Tina Raab, Caroline Schrenk, Michele Schuierer, Alexandra Wiedemann, Daniel Ecker, Carolin Eschenbach, Bernhard Landwehrmeyer, Franziska Lezius, Michael Orth, Sonja Trautmann, Claudia Cormio, Olimpia Difruscolo, Marina de Tommaso, Vittorio Sciruicchio, Claudia Serpino, Elisabetta Bertini, Claudia Mechi, Marco Paganini, Sivia Piacentini, Maria Romoli, Sandro Sorbi, Giovanni Abbruzzese, Emilio Di Maria, Monica Bandettini di Poggio Giovanna Ferrandes, Paola Mandich, Roberta Marchese, Alberto Albanese, Stefano Di Donato, Caterina Mariotti, Paola Soliveri, Cinzia Gellera, Daniela Monza, Chiara Tomasello, Lorenzo Nanetti, Di Maio Luigi, Giuseppe De Michele, Carlo Rinaldi, Cinzia Russo, Elena Salvatore, Tecla Tucci, Ferdinando Squitieri, Tiziana Martino, Sara Orobello, Silvia Alberti, Francesca De Gregorio, Valentina Codella, Nunzia De Nicola, Vittorio Maglione, Anna Rita Bentivoglio, Alfonso Fasano, Marina Frontali, Arianna Guidubaldi, Tamara Ialongo, Gioia Jacopini, Giovanna Loria, Carla Piano, Silvia Romano, Francesco Soleti, Maria Spadaro, Paola Zinzi, Arvid Heiberg, Marleen R van Walsem, Kathrine Bjørgo, Madelein Fannemel, Per Gørvell, Lars Retterstøl, Inga Bjørnevoll, Sigrid Botne Sando, Jaroslaw Slawek, Witold Soltan, Emilia Sitek, Magdalena Boczarska-Jedynak, Barbara Jasinska-Myga, Gregorz Opala, Andrzej Szczudlik, Monika Rudzińska, Magdalena Wójcik, Krzysztof Banaszkiewicz, Malgorzata Krawczyk, Daniel Zielonka, Jerzy Marcinkowski, Anna Ciesielska, Justyna Sempołowicz, Anna Bryl, Aneta Klimberg, Piotr Janik, Anna Kalbarczyk, Hubert Kwiecinski, Zygmunt Jamrozik, Grzegorz Witkowski, Danuta Ryglewicz, Jakub Antczak, Maria Rakowicz, Katarzyna Jachinska, Elzbieta Zdzienicka, Przemyslaw Richter, Jacek Zaremba, Miguel Coelho, Joaquim J Ferreira, Tiago Mestre, Mário M Rosa, Anabela Valadas, Miguel Gago, Carolina Garrett, Maria Rosalia Guerra, Francisco J Barrero, Blas Morales, José Luis López-Sendón Moreno, Esther Cubo, Natividad Mariscal, Jesús Sánchez, Rocío García, Clara Villanueva, Purificacion Pin Quiroga, Mónica Bascuñana, Patricia Trigo Cubillo, Marta Fatàas, José Luis López Moreno, Guillermo García Ribas, Christine Schwarz, Justo García de Yébenes, María José Saiz Artiga, Asunción Martínez-Descals, Pedro J García Ruíz, Vicenta Sánchez, Lorenza Fortuna Alcaraz, María Fuensanta Noguera Perea, María Martirio Antequera Torres, Laura Vivancos Moreau, Ana Rojo Sebastian, Miquel Aguilar Barbera, Dolors Badenes Guia, Laura Casas Hernanz, Gemma Tome Carruesco, Esther Suarez San Martin, Judit López Catena, Jordi Bas, Matilde Calopa, Núria Busquets, Penelope Navas Arques, Aranzazú Gorospe, Inés Legarda, María José Torres Rodríguez, Barbara Vives, Fátima Carrillo, Pablo Mir, María José Lama Suarez, Ghada Loutfi, Eva-Lena Stattin, Laila Westman, Birgitta Wikström, Sven Pålhagen, Elisabeth Björnsson, Jean-Marc Burgunder, Irene Romero, Michael Schüpbach, Sabine Weber Zaugg, Monique S.E. van Hout, Jeroen P.P. van Vugt, A. Marit de Weert, J.J.W. Bolwijn, M. Dekker, K.L. Leenders, J.C.H. van Oostrom, Reineke Bos, Eve M. Dumas, Caroline K. Jurgens, Simon J. A. van den Bogaard, Raymund A.C. Roos, Marie-Noëlle Witjes-Ané, Berry Kremer, C.C.P. Verstappen, Jenny de Souza, Hugh Rickards, Jan Wright, Roger A. Barker, Kate Fisher, Anna Olivia Goyder Goodman, Susan Hill, Ann Kershaw, Sarah Mason, Nicole Paterson, Lucy Raymond, Johnathan Bisson, Monica Busse, Lynda Ellison-Rose, Olivia Handley, Sarah Hunt, Jenny Naji, Kathleen Price, Anne Rosser, Stephen Dunnett, Maureen Edwards, Paul A. De Sousa, Teresa Hughes, Marie McGill, Pauline Pearson, Mary Porteous, Paul Smith, Adam Zeman, Nicol Lambord, Julia Rankin, Liz Burrows, Amy Fletcher, Fiona Laver, Mark Silva, Aileen Thomson, Thomasin Andrews, Andrew Dougherty, Fred Kavalier, Charlotte Golding, Alison Lashwood, Dene Robertson, Deborah Ruddy, Anna Whaite, Michael Patton, Maria Patterson, Colin Bourne, Carole Clayton, Heather Dipple, Jackie Clapton, Janet Grant, Diana Gross, Caroline Hallam, Julia Middleton, Ann Murch, Dawn Patino, Thomasin Andrews, Stefania Bruno, Elvina Chu, Karen Doherty, Nayana Lahiri, Marianne Novak, Aakta Patel, Sarah Tabrizi, Rachel Taylor, Thomas Warner, Edward Wild, Natalie Arran, David Craufurd, Ruth Fullam, Liz Howard, Susan Huson, Lucy Partington-Jones, Nichola Verstraelen, Julie Snowden, Andrea Sollom, Cheryl Stopford, Jennifer Thompson, Leann Westmoreland, Andrea H Nemeth, Gill Siuda, Oliver Bandmann, Alyson Bradbury, Kay Fillingham, Isabella Foustanos, Katherine Tidswell, and Oliver Quarrell
References
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;72(6):971-83 [DOI] [PubMed]
- Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 2004;101(10):3498-503 [DOI] [PMC free article] [PubMed]
- Rubinsztein DC, Leggo J, Chiano M, et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci USA 1997;94:3872–6 [DOI] [PMC free article] [PubMed]
- Arning L, Saft C, Wieczorek S, et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet 2007;122(2):175-82 [DOI] [PubMed]
- Andresen JM, Gayan J, Cherny SS, et al. Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J Med Genet 2007;44(1):44-50 [DOI] [PMC free article] [PubMed]
- Weydt P, Soyal SM, Gellera C, et al. The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease.Mol Neurodegener 2009;4:3 [DOI] [PMC free article] [PubMed]
- Taherzadeh-Fard E, Saft C, Andrich J, et al. PGC-1alpha as modifier of onset age in Huntington disease. Mol Neurodegener 2009;4:10 [DOI] [PMC free article] [PubMed]
- Gusella JF, MacDonald ME. Huntington's disease: the case for genetic modifiers. Genome Med 2009;1(8):80 [DOI] [PMC free article] [PubMed]
- Arning L, Haghikia A, Taherzadeh-Fard E, et al. Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J Mol Med 2010;88(4):431-6 [DOI] [PubMed]
- Orth M, Handley OJ, Schwenke C, et al. Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. PLoS Curr;2 [DOI] [PMC free article] [PubMed]
